A Phase 1B, Open-Label, Dose Escalation Study Evaluating the Safety of BSI-201 in Combination With Chemotherapeutic Regimens in Subjects With Advanced Solid Tumours.

Trial Profile

A Phase 1B, Open-Label, Dose Escalation Study Evaluating the Safety of BSI-201 in Combination With Chemotherapeutic Regimens in Subjects With Advanced Solid Tumours.

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Jun 2016

At a glance

  • Drugs Iniparib (Primary) ; Carboplatin; Gemcitabine; Paclitaxel; Temozolomide; Topotecan
  • Indications Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Sarcoma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors BiPar Sciences
  • Most Recent Events

    • 23 May 2012 Actual patient number changed from 150 to 136 as reported by ClinicalTrials.gov.
    • 23 May 2012 Actual end date Sep 2011 added as reported by ClinicalTrials.gov.
    • 06 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top